Match!
Norihiro Yamaguchi
Beth Israel Deaconess Medical Center
17Publications
9H-index
602Citations
Publications 17
Newest
8050 Background: Identification of somatic molecular alterrations in NSCLC has become evidence-based practice. The success and failure rate of using commercially-available tumor genotyping techniques in routine day-to-day NSCLC pathology samples is not well described. We sought to evaluate the success and failure rate of EGFR mutation, KRAS mutation and ALK FISH. Methods: Clinicopathologic data, tumor genotype success and failure rates were retrospectively compiled and analyzed from 381 patient-...
1 Citations
#1Deepa Rangachari (BIDMC: Beth Israel Deaconess Medical Center)H-Index: 11
#2Norihiro Yamaguchi (BIDMC: Beth Israel Deaconess Medical Center)H-Index: 9
Last.Daniel B. Costa (BIDMC: Beth Israel Deaconess Medical Center)H-Index: 39
view all 11 authors...
Introduction Brain metastases (BM) are common in non-small-cell lung cancer (NSCLC). However, the baseline incidence and evolution of BM over time in oncogene-driven NSCLCs are seldom reported. In this study, we evaluated the frequency of BM in patients with epidermal growth factor receptor (EGFR)-mutated or anaplastic lymphoma kinase (ALK)-rearranged NSCLC.
111 CitationsSource
#1Sohei Nakayama (Keio: Keio University)H-Index: 11
#2Kenzo Soejima (Keio: Keio University)H-Index: 20
Last.Tomoko Betsuyaku (Keio: Keio University)H-Index: 35
view all 15 authors...
10 Citations
#1Sohei Nakayama (BIDMC: Beth Israel Deaconess Medical Center)H-Index: 11
#2Natasha J. Sng (BIDMC: Beth Israel Deaconess Medical Center)H-Index: 6
Last.Shigeru Kobayashi (BIDMC: Beth Israel Deaconess Medical Center)H-Index: 59
view all 15 authors...
The discovery of somatic mutations in epidermal growth factor receptor (EGFR) and development of EGFR tyrosine kinase inhibitors (TKIs) have revolutionized treatment for lung cancer. However, resistance to TKIs emerges in almost all patients and currently no effective treatment is available. Here we show that β-catenin is essential for development of EGFR mutated lung cancers. β-catenin was upregulated and activated in EGFR mutated cells. Mutant EGFR preferentially bound to and tyrosine-phosphor...
31 CitationsSource
#1Sohei Nakayama (BIDMC: Beth Israel Deaconess Medical Center)H-Index: 11
#2Natasha J. Sng (BIDMC: Beth Israel Deaconess Medical Center)H-Index: 6
Last.Shigeru Kobayashi (BIDMC: Beth Israel Deaconess Medical Center)H-Index: 59
view all 15 authors...
Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA The discovery of somatic mutations in epidermal growth factor receptor (EGFR) and the development of EGFR tyrosine kinase inhibitors (TKIs), such as gefitinib and erlotinib, have revolutionized treatment for non-small cell lung cancer (NSCLC). Resistance to TKIs emerges in almost all patients, but currently no effective treatment is available.Therefore, novel strategies to either prevent or overcome resistance are sorely neede...
Source
#1Erik Folch (BIDMC: Beth Israel Deaconess Medical Center)H-Index: 17
#2Adnan MajidH-Index: 22
Last.Daniel B. CostaH-Index: 39
view all 12 authors...
Source
#1Paul A. VanderLaan (BIDMC: Beth Israel Deaconess Medical Center)H-Index: 22
#2Norihiro Yamaguchi (BIDMC: Beth Israel Deaconess Medical Center)H-Index: 9
Last.Daniel B. Costa (BIDMC: Beth Israel Deaconess Medical Center)H-Index: 39
view all 11 authors...
Abstract Introduction Identification of some somatic molecular alterations in non-small-cell lung cancer (NSCLC) has become evidence-based practice. The success and failure rate of using commercially available tumor genotyping techniques in routine day-to-day NSCLC pathology samples is not well described. We sought to evaluate the success and failure rate of EGFR mutation, KRAS mutation, and ALK FISH in a cohort of lung cancers subjected to routine clinical tumor genotype. Methods Clinicopatholo...
55 CitationsSource
#1Hiroyuki YasudaH-Index: 18
#2Eun YoungH-Index: 21
Last.Daniel B. CostaH-Index: 39
view all 24 authors...
4 CitationsSource
#1Lorena Lobo de Figueiredo-Pontes (BIDMC: Beth Israel Deaconess Medical Center)H-Index: 9
#2Daisy Wing Sze Wong (HKU: University of Hong Kong)H-Index: 1
Last.Daniel B. Costa (BIDMC: Beth Israel Deaconess Medical Center)H-Index: 39
view all 11 authors...
Introduction: Anaplastic lymphoma kinase ( ALK ) rearrangements are present in an important subset of non–small-cell lung cancer (NSCLC) and predict for response to the tyrosine kinase inhibitor crizotinib. In this study, we evaluated the yet unknown frequency and functional role of ALK splicing isoforms in NSCLC. Methods: We analyzed 270 cases of NSCLC for ALK kinase domain splicing aberrations and in addition generated constructs with full-length echinoderm microtubule-associated protein-like ...
9 CitationsSource
#1Norihiro Yamaguchi (BIDMC: Beth Israel Deaconess Medical Center)H-Index: 9
#2Antonio R. Lucena-Araujo (BIDMC: Beth Israel Deaconess Medical Center)H-Index: 11
Last.Daniel B. Costa (BIDMC: Beth Israel Deaconess Medical Center)H-Index: 39
view all 8 authors...
Introduction The multitargeted tyrosine kinase inhibitor (TKI) crizotinib is active against ALK translocated non-small-cell lung cancer (NSCLC); however acquired resistance invariably develops over time. ALK mutations have previously been implicated in only a third of resistant tumors. We sought to evaluate alternative mechanisms of resistance and preclinical strategies to overcome these in a cell line driven by EML4-ALK.
48 CitationsSource
12